-
Sep 2016
Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.
Sci Transl MedHundhausen C, Roth A, Whalen E, Chen J, Schneider A, Long SA, Wei S, Rawlings R, Kinsman M, Evanko SP, Wight TN, Greenbaum CJ, Cerosaletti K, Buckner JH -
Nov 2015
Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Sci Transl MedBluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q -
Aug 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
J Clin InvestRigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR -
Apr 2015
Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
J AutoimmunRosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D -
Dec 2013
Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients.
PLoS OneCerosaletti K, Schneider A, Schwedhelm K, Frank I, Tatum M, Wei S, Whalen E, Greenbaum CJ, Kita M, Buckner JH, Long SA -
Dec 2013
IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Clin ImmunolLong SA, Buckner JH, Greenbaum CJ -
Aug 2013
Intersection between genetic polymorphisms and immune deviation in type 1 diabetes.
Curr Opin Endocrinol Diabetes ObesLong SA, Buckner JH -
Jun 2013
Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.
Clin Exp ImmunolBollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ -
Jan 2013
In active relapsing-remitting multiple sclerosis, effector T cell resistance to adaptive T(regs) involves IL-6-mediated signaling.
Sci Transl MedSchneider A, Long SA, Cerosaletti K, Ni CT, Samuels P, Kita M, Buckner JH -
Sep 2012
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
DiabetesLong SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ, Diabetes TrialNet and the Immune Tolerance Network. -
Oct 2011
Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells.
J ImmunolLong SA, Rieck M, Tatum M, Bollyky PL, Wu RP, Muller I, Ho JC, Shilling HG, Buckner JH -
Sep 2011
CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game.
J ImmunolLong SA, Buckner JH -
May 2011
ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors.
Proc Natl Acad Sci U S ABollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, Teng B, Holt GE, Standifer NE, Braun KR, Xie CF, Samuels PL, Vernon RB, Gebe JA, Wight TN, Nepom GT -
Mar 2011
An autoimmune-associated variant in PTPN2 reveals an impairment of IL-2R signaling in CD4(+) T cells.
Genes ImmunLong SA, Cerosaletti K, Wan JY, Ho JC, Tatum M, Wei S, Shilling HG, Buckner JH -
May 2010
Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse.
Cell Mol ImmunolBollyky PL, Evanko SP, Wu RP, Potter-Perigo S, Long SA, Kinsella B, Reijonen H, Guebtner K, Teng B, Chan CK, Braun KR, Gebe JA, Nepom GT, Wight TN
